KLF4 Antibody

1. the downstream targets of KLF4-mCpG binding, guanine nucleotide exchange factors, serve as the effector of KLF4-induced mitochondrial fusion, cell cycle arrest, and cell protection. PMID: 29507094
2. Human and mouse WNT10A mutant palmoplantar and tongue epithelia also display specific differentiation defects that are mimicked by loss of the transcription factor KLF4. PMID: 28589954
3. The KLF4 might be a potential marker to predict prognosis in solid cancer patients. PMID: 29940144
4. SOX5 overexpression increased Kruppel-like factor 4 (KLF4) gene expression, which was decreased by SOX5 silencing. KLF4 knockdown abrogated the suppressive effect of SOX5 overexpression on osteogenic differentiation of hMSCs. PMID: 29890823
5. Results showed that SIRT1 interacts with and deacetylated KLF4. The deacetylation by SIRT1 promoted nuclear accumulation of KLF4 and enhanced the binding of KLF4 to the CLDN5 promoter in the nucleus. PMID: 28888043
6. miR-145 promotes hepatic stellate cell activation and liver fibrosis by targeting KLF4. PMID: 28091538
7. These findings identify a novel regulatory loop between miR-34a and KLF4 during keratinocytes replicative senescence. PMID: 29580988
8. Knockdown of KLF4 promoted the migration and invasion of nonsmallcell lung cancer (NSCLC) cells, whereas rescue of KLF4 expression reduced cell motion ability in miR25overexpressing NSCLC cells. PMID: 29568911
9. the subcellular localization of Klf4 might be related to the resistance of A549 cells to cisplatin. PMID: 29665649
10. Authors observed that saRNAs induced overexpression of KLF4 could promote cell migration/invasion in NCM460 and HCT116 cell lines. PMID: 29274293
11. This is, to our knowledge, the first report of decreased expression of TFF3, SPDEF, KLF4, and goblet cell population in the colon of patients with HSCR. Altered goblet cell function may result in intestinal barrier dysfunction contributing to the development of HAEC. PMID: 29383490
12. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. PMID: 28988130
13. KLF4 activated the transcription activity of iNOS promoter in MH7A cells stimulated by TNF-alpha. This study indicates that KLF4 is important for regulating the expression of iNOS by TNF-alpha in human synoviocytes. PMID: 28744810
14. Anaplastic thyroid cancer cells show high expression of KLF4, and KLF4 expression is necessary for maintaining the undifferentiated phenotype and drug resistance. PMID: 28920531
15. KLF4 could transcriptionally inhibit Cav-1 expression by binding directly to the promoter domain of Cav-1. PMID: 29587259
16. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4 PMID: 29017567
17. Data show that Kruppel like factor 4 (KLF4) was overexpressed in met proto-oncogene protein (c-Met)-overexpressing non-small-cell lung cancer (NSCLC) cells and tissues. PMID: 29624806
18. KLF4 may act as an administered indicator to assess whether adjuvant postoperative pharmaceutical therapy is needed for patients with colorectal cancer. Low KLF4 expression was significantly correlated with reductions of overall survival and recurrence rate. PMID: 28752861
19. Lower expression of KLF4 and NDRG2 in colorectal cancer patients was correlated with poor overall survival. Thus, KLF4 inhibited the proliferation of colorectal cancer cells dependent on NDRG2 signaling, which provides a novel strategy for therapy and early diagnosis of colorectal cancer. PMID: 28656310
20. KLF4 is downregulated in anaplastic meningioma compared with low-grade meningioma subtypes. By manipulating KLF4 expression in anaplastic meningioma stem-like cells, this study demonstrated that KLF4 acts as a tumor suppressor during malignant progression in meningioma, affecting apoptosis, proliferation, invasion, and cell cycle. PMID: 28651379
21. KLF4 was a direct target of miR-212, and miR-212 repressed KLF4 expression in a post-transcriptional manner. Moreover, miR-212-mediated protection effects were abated following KLF4 expression restoration in MPP-induced SH-SY5Y cells, represented as lowered cell viability and enhanced apoptotic rate. PMID: 29611404
22. Results revealed that novel crosstalk between KLF4 and ZEB1 regulated gemcitabine resistance in PDAC. PMID: 28849150
23. This is the first demonstration that dysregulated KLF4 expression associates with poor differentiation of pancreatic cancer. Epigenetic activation of miR-152/DNMT1/KLF4 signaling pathway by dietary DIM causes differentiation and significant growth inhibition of pancreatic cancer cells, highlighting its translational implications for pancreatic and other cancers. PMID: 28659310
24. The present study found that the KLF4 and KLF5 3'-UTR contains one conserved target site of miR-506 and miR-124, and the overexpression of miR-506 and miR-124 inhibited the H2O2-induced upregulation of KLF4 and KLF5 in HCMs. PMID: 28849090
25. KLF4 enhances the sensitivity of cisplatin to ESCC cells through apoptosis induction and cell cycle arrest. PMID: 28694421
26. KLF4 was identified as an important regulatory factor in the host response to fungi and as a controlling element in the IL-6 immune response with a unique expression pattern comparing fungal and lipopolysaccharide stimulation. PMID: 27346433
27. level in vascular endothelium decreased with age PMID: 29030550
28. Results showed the expression levels of KLF4 were increased in bladder cancer (BC) patients which strongly correlated with the expression levels of PTBP1 but inversely correlated with the expression level of miR-145. These findings suggest that KLF4 is likely to positively contribute to carcinogenesis in certain types of BC. PMID: 28380435
29. Transcriptional inhibition of MSI2 expression by KLF4 occurred in multiple PDAC cell lines as well as mouse models of PDAC. Lost expression of KLF4, a transcriptional repressor of MSI2 results in overexpression of MSI2 in PDACs, which may be a biomarker for accurate prognosis. A dysregulated KLF4/MSI2 signaling pathway promotes PDAC progression and metastasis. PMID: 27449499
30. the results of the present study demonstrated that by regulating KLF4, miR145 may be involved in regulating smooth muscle differentiation of ASCs induced by TGFbeta1 and BMP4. PMID: 28440409
31. our findings reveal KLF4 as a key regulator of miR-182 cluster expression in hESCs and a main contributor to its aberrant expression in melanoma and potentially in other tumors PMID: 28412746
32. Surprisingly, 116 genes are directly activated via mCpG-dependent KLF4 binding activity. In-depth mechanistic studies reveal that recruitment of KLF4 to the methylated cis-regulatory elements of these genes result in chromatin remodeling and transcription activation. PMID: 28553926
33. KLF4 transcriptionally repressed FOXO1 expression in glioma cells, contributing to glioma cell invasion and growth. PMID: 27835585
34. Data suggest that KLF4 could promote cell senescence through a complex network: miR-203, survivin, and p21, which were all regulated by overexpression of KLF4 and contributed to cell senescence. PMID: 27531889
35. Our results establish KLF4alpha as a KLF4 isoform that opposes the function of KLF4(FL) and as an important factor in the complex and unresolved role of KLF4(FL) in breast carcinogenesis. PMID: 27323810
36. Kruppel-like factor 4 (KLF4) inactivation in chronic lymphocytic leukemia correlates with promoter DNA-methylation and can be reversed by inhibition of NOTCH signaling. PMID: 27081174
37. Data suggest that the Kruppel-like factor 4 (KLF4) /telomerase reverse transcriptase (hTERT)/MAPK pathway is a potential new therapeutic target for lung cancer. PMID: 27153563
38. The expression of KLF4 was significantly increased in human osteosarcoma tissues compared with the normal tissues. Elevated KLF4 promoted human osteosarcoma cell proliferation and metastasis. Mechanistic studies revealed KLF4 specifically bound the promoter of CRYAB and upregulated CRYAB expression in human osteosarcoma cells. PMID: 27105535
39. In urothelial bladder carcinoma, strong KLF4 expression was associated with higher risk of metastasis and death. KLF4 positively correlates with TWIST1 and vimentin, and inversely with E-cadherin. In vitro, it is accompanied by decreased E-cadherin and beta-catenin, increased vimentin and fibronectin, and enhanced migration/invasion. KLF4 knockdown suppressed TWIST1 expression and EMT, migration and invasion. PMID: 27519276
40. TGF-beta1 down-regulated KLF4 by activating miR-135a-5p, promoting proliferation and metastasis in hepatocellular carcinoma PMID: 27302923
41. our data suggest that KLF4 inhibits epithelial-mesenchymal transition -enhanced hepatocellular carcinoma growth and invasion PMID: 27102441
42. CSF and plasma expression of KLF4 mRNA was significantly decreased around 1-3 days after subarachnoid hemorrhage and remained lower than in controls. PMID: 28893694
43. PARP1 recruits KLF4 to activate telomerase expression and stem cell pluripotency, indicating a positive regulatory role of the PARP1-KLF4 complex in telomerase expression in cancer and stem cells. PMID: 28985359
44. KLF2 and KLF4 serve as important regulators that promote hemoglobin alpha expression in the endothelium. PMID: 28825355
45. Loss of KLF4 expression is associated with T-cell acute lymphoblastic leukemia. PMID: 27872496
46. IRF4 protects arteries against neointima formation by promoting the expression of KLF4 by directly binding to its promoter. PMID: 28851732
47. High KLF4 expression is associated with breast cancer tumorigenesis. PMID: 28068319
48. High KLF4 expression is associated with melanoma. PMID: 28068326
49. KLF4 transactivates Ch25h and LXR, thereby promoting the synergistic effects between ECs and macrophages to protect against atherosclerosis susceptibility. PMID: 28794002
50. findings evidence a positive correlation between SIRT1 and BCL6 expression increase in follicular lymphomas (FL) . SIRT1 methylation decreases in FL and diffuse large-B cell lymphomas (DLBCL)and this parallels the increase of KLF4, DAPK1 and SPG20 methylation PMID: 28324774

Show More

Hide All

HGNC: 6348

OMIM: 602253

KEGG: hsa:9314

UniGene: Hs.376206